Liposomal forms of rhenium cluster compounds: enhancement of biological activity.
Liposomal formulations of dinuclear cluster rhenium (Re) compounds were used in biochemical trials. Interaction of liposomal forms of some Re compounds with red blood cells in experiments in vitro showed strong cell-stabilizing properties. In the models of tumor growth and hemolytic anemia in vivo, liposomal forms had better therapeutic effects in comparison with their solutions. The process of formation of liposomes of cluster Re compounds with different organic ligands was investigated by the method of electronic absorption spectra and mechanism of their interactions with lipids is proposed. Encapsulation of cluster Re compounds to lipid coating may have activation significance for the quadruple Re-Re bond.
Shtemenko
Natalia I
NI
Department of Biophysics and Biochemistry, Dnipropetrovs'k National University, 149/28 Gagarin av., Dnipropetrovs'k 49107, Ukraine, (phone: +38-562-776 6179; fax: +38-562-473 316).
Zabitskaya
Elena D
ED
Department of Biophysics and Biochemistry, Dnipropetrovs'k National University, 149/28 Gagarin av., Dnipropetrovs'k 49107, Ukraine, (phone: +38-562-776 6179; fax: +38-562-473 316).
Berzenina
Oksana V
OV
Department of Inorganic Chemistry, Ukrainian State Chemical Technology University, Gagarina av. 8, Dnipropetrovs'k 49005, Ukraine.
Yegorova
Dina E
DE
Department of Inorganic Chemistry, Ukrainian State Chemical Technology University, Gagarina av. 8, Dnipropetrovs'k 49005, Ukraine.
Shtemenko
Alexander V
AV
Department of Inorganic Chemistry, Ukrainian State Chemical Technology University, Gagarina av. 8, Dnipropetrovs'k 49005, Ukraine.
D000744:Anemia, Hemolytic, Autoimmune / Q000139:chemically induced / Q000188:drug therapy*; D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry* / Q000494:pharmacology* / Q000627:therapeutic use; D015195:Drug Design; D004912:Erythrocytes / Q000737:chemistry / Q000187:drug effects*; D006801:Humans; D008024:Ligands; D008081:Liposomes; D009374:Neoplasms, Experimental / Q000139:chemically induced / Q000188:drug therapy; D009942:Organometallic Compounds / Q000737:chemistry* / Q000494:pharmacology* / Q000627:therapeutic use; D011817:Rabbits; D051381:Rats; D017208:Rats, Wistar; D012211:Rhenium / Q000737:chemistry*; D013056:Spectrophotometry, Ultraviolet; D013329:Structure-Activity Relationship
D000970:Antineoplastic Agents; D008024:Ligands; D008081:Liposomes; D009942:Organometallic Compounds; D012211:Rhenium